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(Correspondence should be addressed to A Aranda; Email: aaranda@iib.uam.es)AbstractDNA methylation is the best studied epigenetic factor, playing a key role in producing stable changes in gene expression,
thus defining cell identity and function and adapting cells to environmental changes. DNA methylation has also been
recently shown to mediate cell responses to physiological endocrine signals. Moreover, alterations of the normal DNA
methylation pattern can also contribute to the development of endocrine and metabolic diseases and can explain the
relationship between an individual’s genetic background, the environment, and disease. It should be remarked that
although DNA methylation and demethylation are active processes, epigenetic changes produced during development
can impact adult processes, establishing the idea that endocrine function can be persistently affected by events occurring
in early life. Given the complexity of the endocrine system, both genetic and epigenetic processes, including DNA
methylation, must be involved in its proper development and functioning. In this study, we summarize the recent
knowledge in the field of DNA methylation and endocrinology. Given that DNA methylation can be involved in a number of
endocrine and metabolic disorders, understanding and manipulating this modification opens a new door for preventing
and treating endocrine diseases.Journal of Molecular Endocrinology (2011) 47, R75–R89What is epigenetics?
The term ‘epigenetics’ has classically been used to
explain phenotypic events that cannot be described by
genetic mechanisms. Waddington (1942) coined the
term ‘epigenetics’ in the 1940s, defining epigenetics
as ‘the branch of biology that studies the causal
interactions between genes and their products, which
bring the phenotype into being’. An updated definition
now considers epigenetic conditions to be those that
affect gene expression without changing the nucleotide
sequence, in a way that can involve mitotic, or, less
frequently, meiotic inheritance (Holliday 2006), con-
ferring a certain stability on epigenetic events through
cell generations. Very recently, Skinner et al. (2010)
have defined epigenetics as ‘molecular factors and
processes around DNA that are mitotically stable and
regulate genome activity independent of DNA
sequence’. Although most of the cells in a multicellular
organism share the same genetic information, an
organism produces many different cell types during its
development, each characterized by a typical gene
expression profile and by specific functions. Conse-
quently, cell differentiation might be considered as aJournal of Molecular Endocrinology (2011) 47, R75–R89
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modification identified was DNA methylation in the
1970s (Holliday & Pugh 1975). However, epigenetics
also addresses covalent modifications of histones
and the mechanisms through which they alter chroma-
tin structure (Turner 1998). Other gene regulation
mechanisms such as non-coding RNA are also included
among epigenetic pathways (Aguilera et al. 2010).
Epigenetic processes are likely to be expanded in
the future. For example, the recent identification
of hydroxymethylcytosine residues is a new epi-
genetic mark whose function remains to be elucidated
(Kriaucionis & Heintz 2009). In this review, we will
focus on only one of these epigenetic modifications,
namely DNA methylation.DNA methylation
DNA methylation is the most extensively investigated
epigenetic modification because more than two
decades ago it was shown to play a critical role in
cancer. Feinberg & Vogelstein (1983) demonstrated for
the first time that tumor cells can lose DNA methylationDOI: 10.1530/JME-11-0059
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tories identified a number of tumor suppressor genes
that often become aberrantly hypermethylated and
repressed in cancer cells (Feinberg 2007). Later on,
investigations moved outside of the cancer field and
today it is well established that DNA methylation is
essential for normal development and differentiation
in mammals (Fraga 2009). DNA methylation consists
of the covalent addition of a methyl group at the
5-position of cytosines. This normally occurs on a
cytosine followed by a guanine, called a CpG dinu-
cleotide. This dinucleotide normally occurs at low
frequency in vertebrate DNA. However, stretches of
DNA with a high CCG content and a high frequency of
CpG dinucleotides relative to the bulk genome have
been defined as CpG islands by Gardiner-Garden &
Frommer (1987). Most CpG dinucleotides are methyl-
ated, but those located in CpG islands are usually
unmodified. Although CpG islands are located pre-
ferentially in gene promoters or regulatory regions,
most of these dinucleotides are nonetheless found
in repetitive DNA elements. The DNA methylation
pattern is removed in the early embryo and then
reconstituted at the time of implantation (Kafri et al.
1992). DNA methylation is also responsible for genomic
imprinting, securing monoallelic gene expression by
repressing expression of the paternal or maternal
genes, for X-chromosome inactivation in females, and
for silencing of parasitic elements (Payer & Lee 2008,
Kacem & Feil 2009).
Although methylation of cytosine bases (mCs) in
CpG dinucleotides is the principal form of DNA
methylation, other modifications such as methylation
of cytosine in CpNpG trinucleotides (where N denotes
any base) or hydroxymethyl cytosines (hmCs) also exist,
and all these modifications define the DNA methylome
of a cell. A full methylome analysis should include these
modifications in addition to mCG, although the
biological function of mCGs and hmCs has not yet
been clarified (Beck 2010). Methylome analysis, as well
as the analysis of other epigenetic marks, will be needed
to define the epigenome map characteristics of normal
development and differentiation, including develop-
ment of endocrine glands, and for the identification of
genomic regions involved in endocrine and non-
endocrine disorders. Another unresolved issue in
DNA methylation is that of bisulfite sequencing, the
currently used method of analysis that relies on the
conversion of unmethylated cytosine residues to uracil
cannot distinguish between methylation and hydro-
xymethylation, and densely hydroxymethylated regions
of DNA may be underrepresented in quantitative
methylation analyses (Huang et al. 2010). In 2009, the
first genome-wide, single-base resolution maps of
methylated cytosines in a mammalian genome have
been resolved (Lister et al. 2009). Surprisingly, and inJournal of Molecular Endocrinology (2011) 47, R75–R89contrast with differentiated cells, a significant fraction
(almost one-quarter) of the methylation found in
embryonic stem cells occurred in a non-CG context.
This modification was lost on induction of differen-
tiation and was restored in induced stem cells. These
interesting results provide a foundation for future
studies exploring this key epigenetic modification in
human disease and development and to analyze its role
in endocrine function.DNA methyltransferases (DNMTs):
hormonal control of DNMT expression
S-adenosylmethionine acts as a methyl donor for
addition of the methyl group to cytosine residues
within CpG dinucleotides. This reaction is catalyzed by
DNA methyltransferase (DNMT) enzymes. In mam-
mals, DNMTs include four members, in two families
that are structurally and functionally distinct. The
DNMT3 family establishes the initial CpG methylation
pattern, whereas DNMT1 maintains this pattern during
DNA replication (Mortusewicz et al. 2005, Chen & Li
2006). The DNMT3 family has three members:
DNMT3A, DNMT3B, and DNMT3L (DNMT3 like).
DNMT3L does not have enzymatic activity but may
function as a regulator of DNA methylation. Inacti-
vation of DNMT1, DNMT3A, and DNMT3B by gene
targeting was found to cause lethality in mice, either
pre- or post-natally. DNMT3A and DNMT3B act
basically as de novo methyltransferases establishing the
DNA methylation patterns at early developmental
stages, although they have also a function at later stages
maintaining global DNA methylation levels. In contrast,
DNMT1 lacks de novo methyltransferase activity but
serves as a maintenance for methyltransferase by
copying the DNA methylation pattern from the
parental strand to the daughter strand after DNA
replication (Robertson 2005; Fig. 1).
Recent results suggest that DNMT expression is
under hormonal control. For instance, DNMT3A,
DNMT3B, and DNMT1 are under the regulation of
female sex steroid hormones during the menstrual cycle
(Yamagata et al. 2009, van Kaam et al. 2011), and aberrant
expression of DNMTs was observed in endometriosis
(Wu et al. 2007, van Kaam et al. 2011). On the other hand,
estradiol increases DNMT3A and DNMT3B expression
in the dorsal hippocampus, and increased methylation
of memory suppressor genes (e.g. reelin) may be crucial
for estradiol to enhance memory consolidation (Zhao
et al. 2010). Paradoxically, even though congenital
hypothyroidism is associated with impaired cognitive
development, increased methylation of the reelin and
BDNF genes is also found in the hippocampus of
hypothyroid rats (Sui & Li 2010), showing the complex
effects of thyroid hormones in brain development.www.endocrinology-journals.org
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Figure 1 The DNA methyltransferases DNM3A and DNMT3B are responsible for de novo methylation,
whereas DNMT1 is in charge of maintaining methylation after DNA replication by modifying the daughter
strand. The daughter strands of DNA following replication are unmethylated. Hemi-methylation status is
recognized by DNMT1, which is recruited to the replication fork, and then restores the parental methylation
pattern. Unmethylated CpGs are shown by empty circles and the methylated nucleotides by red circles.
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and postpubertal prostatitis observed after exposure
to the antiandrogenic compound vinclozolin during
gonadal sex determination could also be related to
changes in DNMTs expression in the testis and prostate
(Anway & Skinner 2008, Anway et al. 2008, Cowin
et al. 2010). Furthermore, changes in DNMT1 expre-
ssion have been shown to contribute to both prostate
cancer initiation and promotion (Esteller 2005,
Feinberg et al. 2006).
Peptide hormones can also regulate DNMT
expression. For instance, autocrine human GH
(hGH) increases expression of DNMT1, DNMT3A,
and DNMT3B in mammary carcinoma cells and it has
been postulated that the oncogenic effects of hGH in
these cells is secondary to the increase in DNMTs that in
turn causes silencing of the plakoglobin gene by
hypermethylation of its promoter CpG island (Shafiei
et al. 2008).
Although DNMT expression and function can be
regulated by hormones, the cited studies show mostly
correlative effects and the molecular mechanisms
involved are still poorly understood.Gene repression by DNA methylation: link to
histone modifications
In general, DNA methylation leads to repression of
gene expression. Normally, methylated genes are either
not transcribed into mRNA or transcribed at a markedly
reduced rate (Esteller 2005, Feinberg et al. 2006).
Cytosine methylation alters the structure of the major
groove of DNA, and this can block the recruitment of
transcription factors to their binding sites and inhibit
gene transcription. However, although DNA methyl-
ation can affect association of several transcription
factors (including E2F, MLTF, or CTCF) to their
recognition sites, other transcription factors, such as
Sp1, can still bind to methylated DNA. In addition to
altering transcription factor binding, DNA methylation
allows the recruitment of proteins with high affinity for
methylated CpGs (methyl binding proteins or MBDs)www.endocrinology-journals.orgthat can repress gene expression. Five MBDs have been
identified (MeCP2, MBD1, MBD2, MBD3, and MBD4),
and excluding MBD4, they induce transcriptional
silencing (Bird & Wolffe 1999). Histone deacetylation
is linked to chromatin compaction and transcriptional
repression, and after binding to methylated CpG
dinucleotides, the MBD MeCP2 interacts with core-
pressor complexes containing histone deacetylases
(HDACs) and Sin3a inducing gene silencing (Jones
et al. 1998, Nan et al. 1998). Interestingly, the same
corepressor complexes are recruited to hormone
nuclear receptors and mediate ligand-independent
repression of gene expression by some unliganded
non-steroid receptors and by antagonist-bound steroid
receptors (Aranda & Pascual 2001). Other MBDs
interact directly with DNMT1 and with one or more
HDACs (Fuks et al. 2000, 2001, Robertson et al. 2000,
Rountree et al. 2000, Aapola et al. 2002, Kimura &
Shiota 2003), suggesting the existence of a functional
cooperation between CpG methylation and histone
deacetylation that silences gene expression in a
stable manner.
The N-terminal tails of histones can undergo
different posttranslational modifications that seem to
have a crucial influence on chromatin structure and are
linked to either transcriptional repression or activation
(Kouzarides 2007). Whereas histone acetylation is
normally associated with transcriptionally active chro-
matin, methylation of histone H3 at particular residues
can lead to local formation of heterochromatin, which
in contrast with DNA methylation that causes stable
transcriptional repression is fully reversible. The
existence of a cross talk between DNA methylation
and histone modifications, which can be mediated by
interactions between histone methyltransferases and
DNMTs, has been recently demonstrated (Fig. 2).
Relationships between DNA methylation and histone
modification have implications for understanding
normal development as well as somatic cell reprogram-
ming and tumorigenesis (Cedar & Bergman 2009).
Thus, histone deacetylation facilitates methylation of
H3K9 by the histone methyltransferase G9a. Methyl-
ation of this residue facilitates the recruitment of theJournal of Molecular Endocrinology (2011) 47, 75–89
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Figure 2 DNA methylation causes gene silencing. Transcriptionally active chromatin is characterized by
unmethylated DNA and binding of transcription factors (TF) with recruitment of coactivators (CoA) and
histone-modifying enzymes such as histone acetyltransferases (HATs), methyltransferases (HMTs), and
demethylases (HDMTs), which induce among other modifications of histone acetylation and H3 di- or
tri-methylation in lysine 4 (H3-K4me, a marker of active chromatin). CpG methylation (Me-CpG) silences
gene expression by recruitment of methyl-binding proteins (MBDs), the heterochromatin protein HP-1,
corepressor (CoR) complexes containing histone deacetylases (HDACs), and histone methyltransferases
leading to deacetylation of the histone tails and methylation of H3 in lysine 9 (H3-K9me). These silencing
complexes produce chromatin compaction. Many other epigenetic factors are also known to control gene
transcription and silencing and therefore this figure illustrates only an example of regulation of gene
expression.
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heterochromatinization. The histone methyltransferase
G9a also recruits DNMT3A and DNMT3B, inducing
de novo DNA methylation, at the final step of silencing
of pluripotency genes (Feldman et al. 2006). These
functions of the histone methyltransferase-containing
complexes appear to play an important role in post-
implantation gene repression by DNA methylation and
represent a basic example of the cross talk between
DNA methylation and histone posttranslational
modifications.DNA methylation and endocrine diseases
Epigenetic changes are not only responsible for normal
development, but they are also involved in disease.
Genetic lesions, including mutations, deletions, or
breakages, are well known to produce disorders in
humans, but there is increasing evidence that diseases
can also be caused by epigenetic alterations. Changes in
DNA methylation can cause silencing of normally active
genes or activation of normally silent genes. This
could occur in cancer, in hereditary disorders resulting
from DNA methylation defects, and in late-onset
diseases caused by the interaction of genomic, epige-
netic, and environmental changes (Robertson 2005,
Feinberg 2007).
The Beckwith–Wiedemann syndrome, an overgrowth
disorder characterized by an increased risk of cancer
and different malformations, is an example of a single-
gene epigenetic disease. Some patients with Beckwith–
Wiedemann syndrome show loss of imprinting of
insulin-like growth factor 2 (IGF2), leading to anJournal of Molecular Endocrinology (2011) 47, R75–R89increase in the levels of this growth factor (DeBaun
et al. 2002). A human disorder with multiple hormone
resistance, the pseudohypoparathyroidism type IA
(PHPIA), is also caused by tissue-specific differential
imprinting of splice variants of the guanine nucleotide
regulatory protein (encoded by GNAS1; Lalande 2001).
Other class of monogenic diseases involves mutation of
genes involved themselves in methylation machinery.
For instance, Rett syndrome is caused by mutations that
affect the methyl-CpG-binding protein MeCP2. Rett
syndrome is a neurodevelopmental disorder that affects
mainly females. Among other symptoms, affected
patients can have seizures, present intellectual disability
with learning difficulties, and have no verbal skills. This
phenotype argues for the primacy of MeCP2, as
opposed to other MBDs, in the silencing mechanism
associated with DNA methylation, at least in the central
nervous system. In Rett syndrome, DNA methylation is
not altered, but gene silencing is abnormal because
DNA methylation goes unrecognized (Bienvenu &
Chelly 2006).
Gene hypomethylation is a common event in cancer,
although site-specific hypermethylation and other
epigenetic chromatin modifications are also found in
tumors (Cedar & Bergman 2009). A large number of
cancer-related genes that are silenced or activated by
aberrantly methylated CpG islands have been identified
in different types of tumors indicating that epigenetic
events play a key role in tumorigenesis (Costello et al.
2000). Many growth-promoting genes are activated in
tumors due to DNA hypomethylation and, not surpris-
ingly, some major hypermethylated genes in cancer
include tumor suppressors (Feinberg & Vogelstein
1983). In the case of an imprinted tumor suppressorwww.endocrinology-journals.org
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cause a total loss of its tumor suppressor function
because the other allele is already inactive (Feinberg
et al. 2006). On the contrary, loss of imprinting of an
oncogene can lead to overexpression of the oncogenic
protein and consequently to increased risk of tumor
formation. Importantly, lymphocytes in w10% of the
human population have loss of imprinting at the IGF2
locus. Interestingly, the IGF2 receptor (IGFR2) gene
that functions as a tumor suppressor is not imprinted in
humans but is imprinted and has a maternal expression
in mice. Therefore, it has been predicted that the
incidence of tumors resulting from IGFR2 inactivation
should be lower in humans than in mice (Jirtle &
Skinner 2007).
DNA methylation of tumor suppressor genes is
common in endocrine cancer. To give a few examples,
epigenetic gene silencing of tumor suppressor genes,
including E-cadherin, PTEN, RASSF1A, and FGFR2,
and of differentiation-related genes, such as TSH
receptor and the sodium-iodide symporter, has been
reported in thyroid cancers (Kondo et al. 2006, 2007,
Xing 2007). Frequent promoter hypermethylation of
the APC, RASSF1A, or Rap1GAP tumor suppressors is
found in parathyroid tumors (Juhlin et al. 2010). von
Hippel–Lindau inactivation by promoter methylation is
an important pathway for the development of malig-
nant sporadic pancreatic endocrine tumors (Schmitt
et al. 2009) and pheochromocytomas (Cascon et al.
2004), and loss of pRb and neuronatin expression is
associated with promoter hypermethylation in pituitary
adenomas (Simpson et al. 2000, Dudley et al. 2009, Revill
et al. 2009).
The existence of hormone-independent tumors is a
substantial problem for the treatment of several
endocrine tumors with hormone antagonists. Hyper-
methylation can selectively silence multiple promoters
of steroid receptors in hormone-dependent cancers,
including ovarian, endometrial, breast, and prostate
cancer. Aberrant DNA methylation of the promoter
region of estrogen (ER), progesterone (PR), and
androgen (AR) receptors can play an important role
in the loss of hormone dependence, although resist-
ance to hormonal treatment can appear even in the
presence of steroid receptor expression (Lapidus et al.
1996, Jarrard et al. 1998, Sasaki et al. 2003, Asada et al.
2008). Interestingly, DNMT inhibitors such as 5-aza-2 0-
deoxycytidine and HDAC inhibitors such as trichostatin
A have been successfully used to induce ER expression
in ER-negative breast cancer cells (Ferguson et al. 1995)
and to sensitize hormone-resistant ER-negative breast
cancer cells to tamoxifen (Jang et al. 2004). It is
increasingly recognized that epigenetic gene silencing
plays a major role in tumor initiation and progression
in hormone-dependent cancers. Indeed, in the first
genome-wide DNA methylation profiling according towww.endocrinology-journals.orgthe receptor status of breast cancer, it has been found
that ER/PR status affects the global DNA methylation
profile (Li et al. 2010).
Expression of other non-steroid hormone nuclear
receptors has also been found to be inactivated by
promoter DNA methylation in tumors. This is the case
for the thyroid hormone receptor b isoform (TRb),
which can function as a tumor suppressor (Martinez-I-
glesias et al. 2009, Garcia-Silva et al. 2011). The TRb
promoter is methylated in early stage breast cancer
tumors (Li et al. 2002). The same occurs with the
retinoic acid receptor b (RARb). Retinoic acid (RA), an
active metabolite of vitamin A, plays a key role in
development and has important antitransforming
actions in many types of cancer cells. RARb is one of
the tumor suppressor genes that are more often
epigenetically inactivated in tumors (Esteller et al.
2002). Very recently, it has been found that RA plays a
key role in the fate of intestinal cells through regulation
of DNA demethylase activity (Rai et al. 2010). DNA
demethylation has been proposed to involve the
cooperative actions of proteins from the cytidine
deaminase family (activation-induced deaminase and
Apobec2), the G:T mismatch-specific glycosylase family
(MBD4), and a DNA repair protein family (GADD45;
Rai et al. 2008). However, the role of GADD45 in
promoting DNA demethylation is still controversial (Jin
et al. 2008) and DNA methylation is conserved in
genetically modified mice lacking GADD45 (Engel et al.
2009). Loss of the adenomatous polyposis coli (APC)
tumor suppressor gene is the key initiating step in a
model of genetic and epigenetic events that lead to
colorectal cancer. Loss of APC causes upregulation of a
DNA demethylase system and the concomitant hypo-
methylation of key intestinal cell fating genes, whereas
RA strongly downregulates demethylase components,
thereby promoting DNA methylation of key genes
and helping progenitor cells commit to differentiation
(Rai et al. 2010).Hormonal control of DNA methylation/
demethylation at target promoters
Although the mechanisms of DNA demethylation are
not yet totally understood and remain a controversial
issue (Ooi & Bestor 2008), recent data obtained
studying the effect of hormones, mainly ligands of
nuclear receptors, on transcription of their target genes
indicate that they can mediate active DNA demethyl-
ation occurring independently of DNA replication.
One of the first evidence was obtained with the
glucocorticoid receptor (GR). Glucocorticoids cause
local DNA demethylation of the tyrosine aminotrans-
ferase (Tat) gene around a glucocorticoid response
element that is located 2.5 kb upstream of theJournal of Molecular Endocrinology (2011) 47, 75–89
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Figure 3 Proposed model for active DNA methylation/demethyla-
tion at steroid hormone target promoters. The process would
involve deamination to thymidine resulting in T/G mismatch.
The action of a thymine DNA glycosylase (TDG) such as MBD4
would initiate a process of repair that would be completed by the
base excision repair (BER) machinery leading to unmethylated
CpG, which can then be again methylated by DNMTs starting
a new cycle.
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demethylation is a consequence of an active mechanism
that involves the creation of DNA nicks 3 0 to the
methylcytidine and the participation of a demethylase
initiating a base excision repair.
GR-dependent demethylation was slow since it was
detected after a few hours of stimulation. However, a
rapid methylation/demethylation at the ER target gene
pS2 has been observed in breast cancer cells (Kangas-
peska et al. 2008, Metivier et al. 2008). It had been
previously shown that ER is recruited in a cyclic manner
to the pS2 promoter and that this is followed by the
assembly of coactivators, which in turn provokes local
structural changes in chromatin. This allows the
engagement of the basal transcription machinery and
the activation of the RNA polymerase II, which is then
followed by the recruitment of corepressor complexes
and the initiation of the next transcriptional cycle
(Metivier et al. 2003). Remarkably, these changes are
accompanied by changes in the methylation of CpG
dinucleotides in the pS2 promoter and breaks in the
sugar–phosphate backbone of DNA. Cyclical methyl-
ation and demethylation of CpG dinucleotides had a
periodicity of around 100 min, implying the existence
of an active demethylation process. Methylation takes
place at each transcriptional cycle after the occupancy
of ER and polymerase II and is connected with the
recruitment of MeCP2 and DNMT1 to the pS2
promoter. Recruitment of MBD2 and MBD3 occurs
later, simultaneously with the recruitment of the
remodeling complex NuRD. CpG methylation at the
pS2 promoter is strand specific, occurring primarily in
the transcribed strand. DNMTs appear to exhibit dual
actions during these cycles, being involved in CpG
methylation and also in active demethylation of
5mCpGs through deamination. As stated above,
demethylation of the Tat gene involves the formation
of DNA nicks, and CpG methylation/demethylation at
the pS2 promoter also involves a base excision repair
process with base substitution (Metivier et al. 2008). The
following process has been suggested: deamination of
5mC by DNMT3A or DNMT3B would result in a T/G
mismatch, which would be repaired by a thymine DNA
glycosylase by excision of the mispaired cytosine,
generating an abasic residue. This would be followed
by the action of apurinic/apyrimidinic endonuclease I,
which would create a single nucleotide gap by cleaving
the phosphodiester bond 5 0 to the excised base. Then,
DNA polymerase b would replace the missing nucleo-
tide and finally a DNA ligase would end the repairing
process (Reid et al. 2009; Fig. 3).
Another example of rapid methylation/demethyla-
tion in a hormonally regulated promoter has been
provided by the cytochrome p450 27B1 (CYP27B1), the
final enzyme in vitamin D biosynthesis (Kim et al. 2009).
CYP27B1 gene expression is regulated by two calcemicJournal of Molecular Endocrinology (2011) 47, R75–R89hormones: parathyroid hormone (PTH) and vitamin D.
PTH activates CYP27B1 transcription through stimu-
lation of protein kinases A and C (PKA and PKC),
whereas vitamin D through binding to its nuclear
receptor, VDR, represses CYP27B1 transcription. A
basic helix–loop–helix transcriptional activator (VDR-
interacting repressor, VDIR) binds to the CYP27B1
promoter and VDR interacts with VDIR and represses
transcription by means of recruiting a HDAC corepres-
sor complex (Murayama et al. 2004). Reflecting vitamin-
D-mediated transrepression of the CYP27B1 gene, rapid
methylation of CpG sites is induced by vitamin D in
this gene promoter. This methylation step requires
DNMT1 and DNMT3B. Conversely, treatment with
PTH causes active CpG demethylation of the CYP27B1
promoter. Purification of a VDIR-associated complex
showed the presence of both DNMTs and the DNA
glycosylase MBD4 in the complex. Activation of PKC
by PTH causes MBD4 phosphorylation and activation.
The DNA glycosylase would cause the excision of the
mispaired nucleotide and a base excision repair process
would achieve CpG demethylation of the promoter
(Kim et al. 2009). Thus, the results obtained with the
CYP27B1 promoter further suggest that DNA methyl-
ation/demethylation plays an important role in
hormonal regulation of transcription.
Other member of the CYP superfamily, oxysterol
7a-hydroxylase (CYP7B1), is also regulated by DNA
methylation. The nuclear receptor peroxisome pro-
liferator-activated receptor a (PPARa) represses liver
expression of CYP7B1 in females but not in males.
This inhibition appears to involve a sex-specific
sumoylation of the receptor and is mediated by
methylation of a Sp1 site in the CYP7B1 promoter,
which contains a CpG dinucleotide. Methylation of
this CpG inhibits binding of Sp1 to the promoter.
Furthermore, complexes containing MBDs, NCoR,www.endocrinology-journals.org
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methylated DNA (Yoon et al. 2003), and it was found
that these complexes are involved in inhibition of
CYP7B1 gene transcription by PPARa (Leuenberger
et al. 2009).DNA methylation and the persistent
neonatal effects of glucocorticoids in
the brain
Exposure to stress during neurodevelopment has an
effect on the quality of physical and mental health.
Maternal care might influence hypothalamic–pituitary–
adrenal (HPA) function in the rat through epigenetic
programming of GR expression (Weaver et al. 2007).
In humans, childhood abuse alters HPA stress
responses and increases the risk of suicide. Decreased
levels of GR mRNA and increased methylation of the
GR promoter were found in hippocampus from abused
suicide victims that also showed a decrease in NGFI-A
transcription factor binding. These findings translate
previous results from rat to humans and suggest a
common effect of parental care on the epigenetic
regulation of hippocampal GR expression (McGowan
et al. 2009). The most normally used technique to
induce early life stress is periodic infant–mother
separation during the neonatal period. This causes an
irreversible increase in glucocorticoid secretion with
disruption of the activity of the HPA axis and increased
sensitivity to stress later in life, which are related to
disorders of mood and cognition. Murgatroyd et al.
(2009) have examined the expression of AVP and CRH
in early life stress. These hypothalamic secretagogues
regulate HPA axis activity by increasing ACTH
expression. They found that neonatal stress induces
lifelong hypomethylation of the AVP gene, causing
increased AVP expression, activation of the HPA axis,
and behavioral alterations. They found that hypomethy-
lated CpG residues serve as DNA-binding sites for
MeCP2 that is phosphorylated by CaMKII after
depolarization of hypothalamic cells. Thus, this study
defines this methyl CpG-binding protein as an import-
ant component in the epigenetic programming of
neuroendocrine and behavioral functions.
There is evidence for hypercortisolemia playing a
role in the generation of psychiatric symptoms and for
epigenetic variation within HPA axis genes mediating
behavioral changes also in the adult. When mice are
treated with corticosterone, they exhibit anxiety-like
behavior together with a significant decrease in the
hippocampal mRNA levels of GR and an increase in
the stress-related gene Fkbp5. This gene encodes a
co-chaperone of hsp90 that binds to GR and promotes
cytoplasmic localization of the receptor, regulating GR
sensitivity. Differences were seen in Fkbp5 methylationwww.endocrinology-journals.orgin hippocampus and hypothalamus of glucocorticoid-
treated animals. The same occurs in a mouse hippo-
campal neuronal cell line exposed to corticosterone.
This suggests that DNA methylation plays a role in
mediating effects of glucocorticoid exposure on FKBP5
function, with potential consequences for behavior
(Lee et al. 2010).
Lower weight at birth is associated not only with risk
of metabolic syndrome but also with cardiovascular
disease and hypertension in adulthood (Stein et al.
1996, Heijmans et al. 2008). The renin–angiotensin
system appears to play a role in this process since a
maternal low-protein diet results in undermethylation
of the At1b angiotensin receptor promoter and
early overexpression of this gene in the adrenal
of offspring (Bogdarina et al. 2007). Furthermore,
maternal glucocorticoids modulate this effect on fetal
DNA methylation since treatment of rat dams with the
11-b-hydroxylase inhibitor metyrapone prevents the
epigenetic change and hypertension in the offspring
(Bogdarina et al. 2010). Collectively, these studies
suggest that DNA methylation might have an important
role on the long-term effects of glucocorticoids in
neonatal brains. However, as the absolute changes are
low and the cell-type composition was not always
systematically analyzed, further studies are needed to
determine the functional role of epigenetic factors in
the long-term effects of early development.
The pro-opiomelanocortin (POMC) gene plays an
important role not only in the regulation of the HPA
axis and adrenal development but also in obesity. The
POMC gene is activated in ACTH-dependent Cushing’s
syndrome. This disorder may be a consequence of
activation of the highly tissue-specific POMC promoter
in pituitary and non-pituitary sites. This promoter
contains a CpG island, which is methylated in normal
non-expressing tissues, but is specifically demethylated
in expressing tissues and tumors (Newell-Price et al.
2001). Methylation near the response element for the
tissue-specific POMC activator PTX1 abolishes binding
of this transcription factor that plays a key role in
pituitary development. It has been suggested that the
POMC promoter could show different degree of
methylation in POMC-expressing hypothalamic
neurons, thus influencing food intake and obesity
(Newell-Price 2003).DNA methylation and gonadal hormones
in the developing brain
Many brain sex-specific features arise from effects of the
gonadal steroid hormones, which are exerted during
the perinatal period. Testosterone is converted into
estradiol within developing neurons, and estradiol
mediates several developmental sex differences in cellJournal of Molecular Endocrinology (2011) 47, 75–89
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sible for dimorphic regulation of pituitary gonado-
tropin secretion and for sex-specific behavior
(McCarthy 2008). Alterations in DNA methylation of
genes essential for sexual brain differentiation, includ-
ing ERa, ERb, and the PR themselves, have been
described to be sex and hormonally regulated. Methyl-
ation of the ERa promoter within the preoptic area,
which is crucial for sexual behavior, is influenced by
maternal care during the neonatal period in rodents.
Thus, maternal licking and grooming has been
demonstrated to alter ERa promoter methylation, and
consequently ERa expression, in a sex-specific manner
(Champagne et al. 2006). In addition, methylation of
the ERa gene in the preoptic area is higher in newborn
females than in males or estradiol-treated females, and
sex and hormone-mediated differences in methylation
were also observed at later stages (Kurian et al. 2010).
While ERa activation is required for neonatal brain
masculinization, ERb activation appears to be involved
in brain defeminization and in the regulation of
neuroendocrine functions, since this receptor coloca-
lizes with neuroendocrine hormones such as GnRH,
CRH, oxytocin, vasopressin, or prolactin. CpG methyl-
ation of the ERb gene in the preoptic area, hypo-
thalamus, or hippocampus of newborns is not
significantly influenced by sex or hormonal treatment.
However, there are differences in ERb methylation in
these brain areas in the adult (Schwarz et al. 2010). On
the other hand, whereas in hypothalamus of newborn
animals no sex differences in PR promoter methylation
are detected, significantly lower levels are found in
adolescent females than males. It has been suggested
that gonadal female hormones promote PR methyl-
ation in the hypothalamus, silencing PR expression
during the critical period of sexual differentiation in
the male, a process that is essential for masculine
behavior in the adult.
Whereas DNA methylation can be profoundly
influenced by gonadal hormones during brain develop-
ment, the effect of these hormones in the adult brain
has received less attention. However, it has been
recently reported that testosterone regulates expression
of vasopressin (AVP) within the bed nucleus of the stria
terminalis (BST) in the adult brain. Castration of male
rats strongly inhibits AVP expression in this nucleus,
and this inhibition is reversed on testosterone treat-
ment. It was found that castration results in AVP
promoter methylation at specific CpG sites in the BST.
Conversely, castration significantly increased ERa
mRNA levels by decreasing ERa promoter methylation.
These results suggest that the DNA methylation pattern
of some steroid responsive genes is actively regulated by
gonadal steroid hormones in the adult brain. It is
intriguing the opposite regulation of ERa and AVP
promoter methylation in response to changes in steroidJournal of Molecular Endocrinology (2011) 47, R75–R89hormone levels in the same brain region, and how this
specificity is regulated remains to be elucidated. In any
case, these results indicate that regulation of DNA
methylation in the adult brain could play a role in the
hormonal control of behavior (Auger et al. 2011).Endocrine disruptors and their possible
transgenerational effects
Epigenetic factors can be altered by the environment
(Fraga et al. 2005, Baryshnikova et al. 2008, Stidley et al.
2010), and increasing evidence suggests that a large
variety of environmental and dietary chemicals can
interfere with normal endocrine functions and result in
adverse consequences. Initial animal studies demon-
strated that compounds with estrogenic activity can
disrupt reproductive tract function. However, it is now
evident that different chemical compounds, referred to
as ‘endocrine disruptors’, can either mimic or interfere
with the normal actions of hormones including not
only sexual steroids, but also thyroid, hypothalamic,
and pituitary hormones (Newbold et al. 2006). The
effect of endocrine disruptors is particularly strong
when exposure occurs during fetal or neonatal periods.
If exposure occurs during these critical stages, it can
produce permanent effects that may be observed much
later in life. For instance, exposure of newborn mice to
environmental estrogens causes uterine lesions and
uterine tumors in adults. Mechanistic studies provided
support that estrogens cause both genetic and epige-
netic alterations in developing target tissues. Thus, the
estrogen-responsive genes lactoferrin and c-fos are
permanently upregulated in the uterus after develop-
mental exposure to the estrogen-like compound
diethylstilbestrol (DES) due to hypomethylation of
the promoter region of these genes after exposure to
this chemical (Li et al. 1997, 2003). DES was prescribed
during many years to pregnant women to prevent
spontaneous abortions. More recently, Tang et al.
(2008) identified 14 genes whose methylation patterns
are altered after neonatal treatment with DES or
genistein (other estrogenic compound), among them
the gene encoding the nucleosomal binding protein 1
(NSBP1), a nucleosome core particle binding protein
that plays a role in chromatin remodeling. On the other
hand, bisphenol-A is a non-steroidal estrogen that is
ubiquitous in the environment. Bromer et al. (2010)
have recently demonstrated that methylation of the
Hoxa10 gene was decreased in the reproductive tract of
mice exposed in utero to bisphenol-A. Decreased DNA
methylation led to an increase in binding of ERa to the
Hoxa10 promoter and to increased estrogen-dependent
transcription. Permanent epigenetic alteration of
sensitivity to estrogen may then be a mechanism
through which endocrine disruptors exert their action.www.endocrinology-journals.org
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show lifelong effects in animals has raised the concern
that fetal and neonatal exposure to these compounds in
humans could also produce epigenetic changes and
impact negatively human health. For instance, human
fetuses can be exposed to high estrogen levels, due to
unintentional continuation of birth control pill intake
by the mother before detection of pregnancy. On the
other hand, exposure of the mother to environmental
estrogen disruptors or intake of high levels
of phytoestrogens can affect the fetus and even the
infant during breastfeeding, with possible adverse
consequences (Prins 2008).
Although epigenetic transgenerational inheritance is
a controversial issue at the moment, results obtained
with experimental animals have suggested that adverse
effects caused by endocrine disruptors may be trans-
mitted to subsequent generations. Environmental
factors may induce epigenetic changes in the germ
line, which would be passed to the progeny (Jirtle &
Skinner 2007). In agreement with this hypothesis, the
susceptibility for tumors after treatment with DES was
transmitted to the descendants through the maternal
germ cell lineage (Newbold et al. 1998), and prenatal
exposure to the endocrine disruptors vinclozolin (an
antiandrogenic compound) or methoxychlor (an
estrogenic compound) induced an adult phenotype
in the F1 generation of decreased spermatogenic
capacity and increased incidence of male infertility.
Furthermore, these effects were described to be
transferred through the male germ line to nearly all
males of several generations (Anway et al. 2005).
However, the transgenerational effects have not been
reproduced by other groups (Renner 2009), casting
some doubts on the transmission of the effects of
vinclozolin beyond the F1 generation. In contrast, a
recent study has examined genome-wide promoter
DNA methylation alterations in the sperm of F3
generation rats whose F0 generation mother was
exposed to vinclozolin (Guerrero-Bosagna et al. 2010).
This study has identified 52 different regions with
altered methylation in the sperm promoter epigenome,
suggesting again that an endocrine disruptor could
have the ability to induce epigenetic transgenerational
changes. As the DNA methylation differences reported
in this study are very marginal, further investigations
are needed to fully characterize the putative heritability
of epigenetic factors.Type 2 diabetes, metabolism, and DNA
methylation
Insulin plays a key role in metabolic control, and
therefore, regulation of insulin gene expression has
been extensively analyzed. However, only recently it haswww.endocrinology-journals.orgbeen shown that the insulin promoter is demethylated
specifically in pancreatic b cells both in humans and in
mice. The insulin gene is methylated in mouse
embryonic stem cells and becomes demethylated on
differentiation into insulin-expressing cells. Methyl-
ation of a specific CpG located in a cAMP response
element (CRE) of the insulin promoter inhibits
association of the transcription factors CREB and
ATF2 that bind to the CRE, while inducing MeCP2
recruitment, leading to a strong reduction of promoter
activity (Kuroda et al. 2009). Therefore, promoter
demethylation may play an important role in the
specific expression of the insulin gene in pancreatic
b cells.
Abnormal nutrition during embryonic development
has been shown to influence disease susceptibility in
the descendants. The global prevalence of obesity
and type 2 diabetes is increasing, and parent obesity is
a risk factor for developing obesity in childhood
(Whitaker et al. 1997). In rodents, it has been shown
that when mothers are fed with a high-fat diet (HFD),
male offspring exhibit increased body weight and are
diabetic and insulin resistant. Furthermore, the off-
spring of these males also present insulin resistance,
showing that fathers can start intergenerational inheri-
tance of metabolic diseases (Dunn & Bale 2009).
Accordingly, paternal HFD alters gene expression in
pancreatic b cells of adult female offspring. The Il13ra2
gene, a gene belonging to the Jak–Stat signaling
pathway, presented the highest difference in gene
expression. An epigenetic mechanism appears to
contribute to the altered Il13ra2 expression, since
methylation at CpG K960 of Il13ra2 was significantly
reduced in HFD offspring with respect to controls. This
CpG is located in a putative recognition site for the
transcription factor TCF-1A and for the methylated
DNA binding protein NF-X. These results show that
paternal HFD could affect metabolism of the offspring
by epigenetic regulation of genes important for
pancreatic b cell function (Ng et al. 2010).
Offspring of males fed a low-protein diet also exhibit
metabolic disturbances. Epigenomic profiling of off-
spring livers reveals changes in cytosine methylation
depending on paternal diet, including reproducible
changes in DNA methylation of PPARa, a key lipid
regulator. These results indicate that parental diet
can affect cholesterol and lipid metabolism in offspring
and define a model system to study environmental
reprogramming of the heritable epigenome (Carone
et al. 2010).
Intrauterine growth restriction (IUGR) also increases
susceptibility to age-related diseases, including type 2
diabetes. In a rodent model of IUGR, which develops
diabetes in adulthood, global decreases in DNA
methylation concomitant with a decrease in DNMT1,
MeCP2, and HDAC1 is observed in tissues such as liverJournal of Molecular Endocrinology (2011) 47, 75–89
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that expression of PDX1, a pancreatic and duodenal
homeobox 1 transcription factor critical for b cell
function and development, was permanently reduced
in IUGR b cells and underwent epigenetic modifi-
cations: throughout development, there were epige-
netic histone modifications, but after the onset ofTable 1 Examples of endocrine conditions associated with DNA meth
Endocrine condition Alteration
Beckwith–Wiedemann Loss of imprinting of IGF2
PHPIA Differential imprinting of GNAS1
Endocrine cancers Methylation of tumor suppressor gen
Aberrant promoter methylation of ER
Regulation of DNA demethylase act
Type 2 diabetes Paternal high-fat diet decreases Il13
in pancreatic b cells of the offsprin
Paternal low-protein diet alters PPA
the offspring
Intrauterine growth restriction decrea
methylation as well as DNMT1 an
Permanent methylation of the Pdx1
intrauterine growth restriction
Intrauterine growth restriction cause
methylation in the proximity of gen
b cell function and development
HNF4a methylation in offspring of m
PPARgC1a methylation after overfe
Neuroendocrine disorders
of mood and cognition
Maternal care affects brain GR meth
GR methylation in childhood abuse
AVP hypomethylation and upregulat
infant–mother separation
Glucocorticoids decrease GR expre
methylation of the anxiety-related
Cardiovascular disease and
hypertension in adulthood
Maternal low-protein diet induces un
angiotensin receptor promoter in t
Glucocorticoid administration preven
hypertension in the offspring
Cushing’s syndrome Demethylation of the POMC promot
and tumors
Sexual hormones and
the brain
Maternal care alters ERa promoter m
area of the brain and sexual beha
Higher ERa methylation in the preop
Sexual differences in ERb methylatio
Castration of male rats causes meth
promoter and reduces ERa methy
the stria terminalis
Increased methylation of the memor
by estradiol
Endocrine disruptors Hypomethylation of estrogen-respon
after treatment with DES
Changes in NSBP1 promoter methy
treatment with DES or genistein
Undermethylation of the Hoxa10 gen
tract of mice exposed in utero to b
Increased expression of DNMT3A a
prostate of rats exposed to vincloz
determination
Altered methylation pattern in 52 reg
descendants of rats exposed to vi
Journal of Molecular Endocrinology (2011) 47, R75–R89diabetes in adulthood, the CpG island in the proximal
Pdx1 promoter was methylated, resulting in permanent
silencing of the Pdx1 locus (Park et al. 2008).
Thompson et al. (2010) have generated the first DNA
methylation map at almost 1 million unique sites
throughout the rat genome in normal pancreatic islet
cells, allowing the identification of the changes thatylation changes
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DNA methylation in endocrinology . V GARCI´A-CARPIZO and others R85occur as a consequence of IUGR. Comparison of
growth restricted with normal rats revealed changes in
DNA methylation at a number of novel loci, not limited
to canonical CpG islands or promoters. The specific
loci affected are in proximity to genes with important
roles in b cell function and development, suggesting
that that epigenetic dysregulation is a strong candidate
for propagating the cellular memory of intrauterine
events, causing changes in expression of nearby genes
and long-term susceptibility to type 2 diabetes.
Low birth weight and unhealthy diets are also risk
factors for metabolic disease including type 2 diabetes.
Genetic, non-genetic, and epigenetic data propose a
role of the key metabolic regulator PPARg coactivator
1a (PPARgC1a) in the development of type 2 diabetes.
When challenged with high-fat overfeeding, low birth
weight subjects develop insulin resistance and reduced
PPARgC1a and OXPHOS gene expression. PPARgC1a
methylation was significantly higher in low birth weight
subjects during the control diet. However, PPARgC1a
methylation increased in only normal birth weight
subjects after overfeeding. These changes are revers-
ible, supporting that DNA methylation induced by
overfeeding is reversible in humans (Brons et al. 2010).
Moreover, in a very recent study, it has been shown that
the increased risk of type 2 diabetes in the offspring of
malnourished mothers was associated with the
decreased expression of the orphan nuclear receptor
HNF4a, previously linked with this type of diabetes.
Specifically, a pancreas-specific enhancer of HNF4a
expression is epigenetically inactivated by DNA methyl-
ation in the adult offspring of poorly nourished
mothers, revealing a novel mechanism by which
maternal diet and aging interact through epigenetic
processes to determine the risk of age-associated
endocrine diseases (Sandovici et al. 2011).Conclusions and perspectives
Epigenetic mechanisms may play a key role in normal
endocrine physiology, as well as in the development of
endocrine diseases. A summary of the changes in DNA
methylation observed to date in relation to different
endocrine conditions is illustrated in Table 1. A better
knowledge of the association between epigenetic
mechanisms and endocrine function should lead to a
better understanding of the molecular basis of endo-
crine disorders and could help to the development of
novel therapeutic strategies. DNA methylation acts at
many levels to regulate hormonal actions: during
development, in response to environmental factors
and endocrine disruptors, in endocrine cancer, endo-
crine therapies, etc. Although many aspects of endo-
crine system epigenetics are still unknown, the recent
advances described here shed a new light on thewww.endocrinology-journals.orgimportance of this epigenetic modification in the
functioning of the endocrine glands and on the
response of target tissues to hormones. The recent
development of ultra-high-throughput technologies
will allow the description of the whole genome DNA
modifications that occur in endocrine physiology and
pathology. These data hold the potential of defining
the epigenetic signatures associated with endocrine
disorders for future use as diagnostic markers and can
lead to the development of novel epigenetic drugs with
therapeutic applications in specific endocrinological
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